Read more

February 05, 2020
1 min read
Save

ACC announces lineup for late-breaking trials

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The American College of Cardiology has announced the lineup of late-breaking clinical trials scheduled for presentation at the 2020 Scientific Session.

The ACC Scientific Session will be held March 28 to 30 in Chicago.

The following presentations were among those selected as late-breakers or featured clinical research:

  • VICTORIA, which assessed vericiguat (Bayer/Merck), a soluble guanylate cyclase stimulator, for the treatment of worsening chronic HF with reduced ejection fraction;
  • VOYAGER-PAD, which evaluated rivaroxaban (Xarelto, Janssen/Bayer) for the prevention of CV and peripheral events after lower-extremity revascularization;
  • TAILOR-PCI, which assessed the efficacy of clopidogrel pharmacogenetics;
  • the ACC 2019 Well-Being study;
  • an assessment of combination antiplatelet and anticoagulation therapy for patients with diabetes and CVD from the COMPASS trial;
  • a cost-effectiveness analysis of low-dose colchicine after MI in patients from the COLCOT trial;
  • the 2-year clinical and echocardiographic outcomes of PARTNER 3;
  • the CARAVAGGIO study, an analysis of apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) for venous thromboembolism associated with cancer;
  • the SPYRAL HTN-OFF MED pivotal trial, an assessment of catheter-based renal denervation in patients not taking antihypertensive agents;
  • an analysis of aspirin duration in patients from the AUGUSTUS trial of patients with atrial fibrillation who had ACS or underwent PCI;
  • analyses of patients from ISCHEMIA and ISCHEMIA-CKD based on kidney function, ischemia severity and CAD extent;
  • a randomized study of ticagrelor (Brilinta, AstraZeneca) monotherapy after 3-month dual antiplatelet therapy in ACS;
  • the TWILIGHT-COMPLEX substudy, which analyzed the safety and efficacy of ticagrelor after complex PCI;
  • a randomized study of the efficacy and safety of e-cigarettes for smoking cessation;
  • ODYSSEY HoFH, a study that assessed the efficacy and safety of alirocumab (Praluent, Sanofi/Regeneron) in adults with homozygous familial hypercholesterolemia;
  • an assessment of eicosapentaenoic acid levels and CV outcomes in patients from the REDUCE-IT trial of icosapent ethyl (Vascepa, Amarin);
  • a PARAGON-HF substudy analyzing the effect of sacubitril/valsartan (Entresto, Novartis) on N-terminal pro-B-type natriuretic peptide in patients with HF with preserved ejection fraction; and
  • results from the Global EXPAND study, an assessment of the MitraClip NTR and XTR system (Abbott) in primary mitral regurgitation.

Healio and Cardiology Today will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.